Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002872 · ClinicalTrials.gov registry record · NA
The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease
A NA study, sponsored by Endeavor Health.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT01002872 is a NA study that has completed, run by Endeavor Health. The registered enrollment target is 19 participants.
The verdict
NCT01002872, a NA study, has completed, sponsored by Endeavor Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease (CKD). Targeting FGF23 measurement in CKD patients may impact both the progression of kidney disease and patient mortality.
Interventions
- DRUG placebo
- DRUG Lanthanum Carbonate (Fosrenol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01002872
The ClinicalTrials.gov registry entry for NCT01002872 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01002872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01002872 about?
NCT01002872 is a clinical study titled "The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease". The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease (CKD). Targeting FGF23 measurement in CKD patients may impact both the progression of kidney disease and patient mortali...
What is the current status of trial NCT01002872?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2009-10. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01002872?
The interventions under investigation include: placebo (DRUG), Lanthanum Carbonate (Fosrenol) (DRUG).
Who is sponsoring clinical trial NCT01002872?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.